Article Sidebar
Views pdf: 8
RELATIONSHIP BETWEEN 18F-FDG PET/CT IMAGING, CLINICAL CHARACTERISTICS AND PREDICTION OF PROGRESSION-FREE SURVIVAL IN RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER PATIENTS
Main Article Content
Abstract
Objective: to analyze the correlation between clinical factors and 18F-FDG PET/CT metabolic parameters in predicting 1-year progression-free survival (1-year PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC). Subjects and Methods: A total of 122 RAI-R DTC patients were included in the study. Metabolic parameters were determined, including the SUVmax, SUVmean, and SUVpeak values of the highest lesion, as well as the total MTV and TLG of all lesions (tMTV, tTLG). These parameters were then compared with clinical factors using the Kruskal-Wallis H test and Mann-Whitney U test. ROC curves were used to calculate the cutoff values of the 18F-FDG PET/CT metabolic parameters for predicting 1-year PFS. Results: The values of 18F-FDG PET/CT metabolic parameters were significantly higher in patients aged > 55 years, stage III-IV before 18F-FDG PET/CT, bone metastases, stimulated Tg >170 ng/ml, and Tg-DT ≤ 1 year compared to the other group (p < 0.05). The metabolic parameters predicted 1-year PFS with high sensitivity > 90%, and the cutoff values for log-SUVmax (g/ml), log-SUVmean (g/ml), log-SUVpeak (g/ml), log-TLG (g/ml x cm3) and log-tMTV (cm3) were 1,09; 0,88; 0,87; 1,31 and 0,66, respectively (AUC: 0,90; 0,89; 0,91; 0,91 and 0,89; respectively). Conclusion: 18F-FDG PET/CT metabolic parameters are associated with age, disease stage, bone metastases, stimulated Tg, Tg-DT. These 18F-FDG metabolic parameters may predict 1-year PFS in patient with RAI-R DTC.
Article Details
Keywords
Differentiated thyroid cancer, radioiodine refractory, 18F-FDG PET/CT, metabolic parameters, progression-free survival (PFS).
References
2. Araz M. et al. (2021), "Role of thyroglobulin doubling time in differentiated thyroid cancer and its relationship with demographic-histopathologic risk factors and 18F-fluorodeoxyglucose positron emission tomography/computed tomography parameters". 36 (5), pp. 425-432.
3. Ciappuccini R. et al. (2020), "Tumor burden of persistent disease in patients with differentiated thyroid cancer: correlation with postoperative risk-stratification and impact on outcome". 20, pp. 1-12.
4. Gay S. et al. (2022), "2-[18F] FDG PET in the Management of Radioiodine Refractory Differentiated Thyroid Cancer in the Era of Thyrosin-Kinases Inhibitors: A Real-Life Retrospective Study". 12 (2), pp. 506.
5. Luo Y. et al. (2020), "Clinical, pathological, and molecular characteristics correlating to the occurrence of radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis". 10, pp. 549882.
6. Manohar P. M. et al. (2018), "Prognostic value of FDG-PET/CT metabolic parameters in metastatic radioiodine-refractory differentiated thyroid cancer". 43 (9), pp. 641-647.
7. Robbins R. J. et al. (2006), "Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning", The Journal of Clinical Endocrinology & Metabolism. 91 (2), pp. 498-505.
8. Roy M. et al. (2022), "Using 18F-FDG-PET/CT Metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers". 12 (10), pp. 2381.
9. Santhanam P. et al. (2018), "The relationship of BRAFV600E mutation status to FDG PET/CT avidity in thyroid cancer: a review and meta-analysis". 24 (1), pp. 21-26.
10. Wang H. et al. (2021), "Investigating 18F-FDG PET/CT parameters as prognostic markers for differentiated thyroid cancer: A systematic review". 11, pp. 648658.